| Year |
Citation |
Score |
| 2023 |
Ahmed M, Wuethrich A, Constantin N, Shanmugasundaram KB, Mainwaring P, Kulasinghe A, O'Leary C, O'Byrne K, Sina AA, Carrascosa LG, Trau M. Liquid Biopsy Snapshots of Key Phosphoproteomic Pathways in Lung Cancer Patients for Diagnosis and Therapy Monitoring. Analytical Chemistry. PMID 37224231 DOI: 10.1021/acs.analchem.3c00519 |
0.332 |
|
| 2022 |
Paz-Ares LG, Ciuleanu T, Pluzanski A, Lee JS, Gainor JF, Otterson GA, Audigier-Valette C, Ready N, Schenker M, Linardou H, Caro RB, Provencio M, Zurawski B, Lee KH, Kim SW, et al. Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 36049658 DOI: 10.1016/j.jtho.2022.08.014 |
0.392 |
|
| 2022 |
Sadeghi Rad H, Bahrami T, Layeghi SM, Yousefi H, Rezaei M, Hosseini-Fard SR, Radfar P, Warkiani ME, O'Byrne K, Kulasinghe A. Immunotherapeutic targets in non-small cell lung cancer. Immunology. PMID 35933597 DOI: 10.1111/imm.13562 |
0.413 |
|
| 2022 |
Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O'Byrne K, Kulasinghe A. Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology (Toronto, Ont.). 29: 3044-3060. PMID 35621637 DOI: 10.3390/curroncol29050247 |
0.341 |
|
| 2022 |
Brims FJ, McWilliams A, Harden SV, O'Byrne K. Lung cancer: progress with prognosis and the changing state of play. The Medical Journal of Australia. 216: 334-336. PMID 35352375 DOI: 10.5694/mja2.51474 |
0.36 |
|
| 2022 |
Herath S, Sadeghi Rad H, Radfar P, Ladwa R, Warkiani M, O'Byrne K, Kulasinghe A. The Role of Circulating Biomarkers in Lung Cancer. Frontiers in Oncology. 11: 801269. PMID 35127511 DOI: 10.3389/fonc.2021.801269 |
0.412 |
|
| 2021 |
Malapelle U, Pisapia P, Addeo A, Arrieta O, Bellosillo B, Cardona AF, Cristofanilli M, De Miguel-Perez D, Denninghoff V, Durán I, Jantus-Lewintre E, Nuzzo PV, O'Byrne K, Pauwels P, Pickering EM, et al. Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. Expert Review of Molecular Diagnostics. 1-14. PMID 34570988 DOI: 10.1080/14737159.2021.1985468 |
0.367 |
|
| 2021 |
Kulasinghe A, O'Leary C, Monkman J, Bharti V, Irwin D, Dutta S, Richard DJ, Hughes B, Ladwa R, O'Byrne K. The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC). Lung Cancer (Amsterdam, Netherlands). 160: 73-77. PMID 34455214 DOI: 10.1016/j.lungcan.2021.08.005 |
0.378 |
|
| 2021 |
Rad HS, Rad HS, Shiravand Y, Radfar P, Arpon D, Warkiani ME, O'Byrne K, Kulasinghe A. The Pandora's box of novel technologies that may revolutionize lung cancer. Lung Cancer (Amsterdam, Netherlands). 159: 34-41. PMID 34304051 DOI: 10.1016/j.lungcan.2021.06.022 |
0.465 |
|
| 2021 |
Ahern E, Solomon BJ, Hui R, Pavlakis N, O'Byrne K, Hughes BGM. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time? Journal For Immunotherapy of Cancer. 9. PMID 34083418 DOI: 10.1136/jitc-2020-002248 |
0.39 |
|
| 2020 |
Rajapakse A, O'Leary C, Gundelach R, Deva R, O'Byrne K. Unilateral autoimmune inner ear disease in a patient with lung cancer treated with nivolumab. Oxford Medical Case Reports. 2020: omaa077. PMID 32995031 DOI: 10.1093/omcr/omaa077 |
0.309 |
|
| 2020 |
O'Leary C, Gasper H, Sahin KB, Tang M, Kulasinghe A, Adams MN, Richard DJ, O'Byrne KJ. Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). Pharmaceuticals (Basel, Switzerland). 13. PMID 32992872 DOI: 10.3390/ph13100273 |
0.397 |
|
| 2020 |
Kulasinghe A, Lim Y, Kapeleris J, Warkiani M, O'Byrne K, Punyadeera C. The Use of Three-Dimensional DNA Fluorescent In Situ Hybridization (3D DNA FISH) for the Detection of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer (NSCLC) Circulating Tumor Cells. Cells. 9. PMID 32549278 DOI: 10.3390/cells9061465 |
0.365 |
|
| 2019 |
Pavlakis N, Cooper C, John T, Kao S, Klebe S, Lee CK, Leong T, Millward M, O'Byrne K, Russell PA, Solomon B, Cooper WA, Fox S. Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. Pathology. PMID 31668406 DOI: 10.1016/j.pathol.2019.08.006 |
0.322 |
|
| 2019 |
O'Leary C, Xu W, Pavlakis N, Richard D, O'Byrne K. Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer. Cancers. 11. PMID 31058838 DOI: 10.3390/cancers11050620 |
0.423 |
|
| 2019 |
Zhou J, Kulasinghe A, Bogseth A, O'Byrne K, Punyadeera C, Papautsky I. Isolation of circulating tumor cells in non-small-cell-lung-cancer patients using a multi-flow microfluidic channel. Microsystems & Nanoengineering. 5: 8. PMID 31057935 DOI: 10.1038/S41378-019-0045-6 |
0.352 |
|
| 2018 |
Kulasinghe A, Kapeleris J, Kimberley R, Mattarollo SR, Thompson EW, Thiery JP, Kenny L, O'Byrne K, Punyadeera C. The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer. Cancer Medicine. 7: 5910-5919. PMID 30565869 DOI: 10.1002/Cam4.1832 |
0.406 |
|
| 2018 |
Duffy MJ, O'Byrne K. Tissue and Blood Biomarkers in Lung Cancer: A Review. Advances in Clinical Chemistry. 86: 1-21. PMID 30144837 DOI: 10.1016/bs.acc.2018.05.001 |
0.457 |
|
| 2016 |
Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. The Lancet. Oncology. PMID 27083334 DOI: 10.1016/S1470-2045(16)30033-X |
0.381 |
|
| 2013 |
Yuen HF, Gunasekharan VK, Chan KK, Zhang SD, Platt-Higgins A, Gately K, O'Byrne K, Fennell DA, Johnston PG, Rudland PS, El-Tanani M. RanGTPase: A candidate for myc-mediated cancer progression Journal of the National Cancer Institute. 105: 475-488. PMID 23468463 DOI: 10.1093/Jnci/Djt028 |
0.384 |
|
| 2010 |
Collins IM, Nicholson SA, O'Byrne KJ. A lung cancer responding to hormonal therapy Journal of Thoracic Oncology. 5: 749-750. PMID 20421769 DOI: 10.1097/JTO.0b013e3181d1271d |
0.35 |
|
| 2007 |
Reynolds JV, Muldoon C, Hollywood D, Ravi N, Rowley S, O'Byrne K, Kennedy J, Murphy TJ. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer Annals of Surgery. 245: 707-716. PMID 17457163 DOI: 10.1097/01.sla.0000254367.15810.38 |
0.301 |
|
| 2006 |
Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, Mitchell JD, Richardson D, O'Byrne KJ, Koong AC, Giaccia AJ. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1507-14. PMID 16533775 DOI: 10.1158/1078-0432.Ccr-05-2049 |
0.369 |
|
| 2005 |
Bissett D, O'Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicolson M, Mercier R, Mazabel E, Penning C, Zhang MH, Collier MA, Shepherd FA. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 842-9. PMID 15681529 DOI: 10.1200/JCO.2005.03.170 |
0.353 |
|
| 2004 |
Martin-Ucar AE, Waller DA, Atkins JL, Swinson D, O'Byrne KJ, Peake MD. The beneficial effects of specialist thoracic surgery on the resection rate for non-small-cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 46: 227-32. PMID 15474671 DOI: 10.1016/j.lungcan.2004.03.010 |
0.373 |
|
| 2004 |
Sedrakyan A, Van Der Meulen J, O'Byrne K, Prendiville J, Hill J, Treasure T. Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis. The Journal of Thoracic and Cardiovascular Surgery. 128: 414-9. PMID 15354101 DOI: 10.1016/j.jtcvs.2004.04.027 |
0.41 |
|
| 2002 |
Santhanam S, Decatris M, O'Byrne K. Potential of interferon-alpha in solid tumours: part 2. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 16: 349-72. PMID 12408739 |
0.372 |
|
| Show low-probability matches. |